Astrazeneca Ab

Astazeneca Ab

Anna Ingrid Kristina Berggren

Jason Grant Kettle

Sameer Pralhad Kawatkar

Qibin Su

Ina Terstiege

Stefan Schiesser

Johan R Johansson

Yafeng Xue

Karl Magnus Nilsson

Matti Juhani Lepistö

Matti Juhani Lepisto

Peter Greasley

Annika Birgitta Margareta Astrand

Stig Jonas Boström

Hui-Fang Chang

Annika Birgitta Margareta Åstrand

Stig Thomas Elebring

Emma Terricabras

Johan Michael Wilstermann

Annika Birgitta Margareta ÅStrand

The present application relates to chemical compounds of Formula (A), and pharmaceutically acceptable salts thereof, that inhibit IRAK4 and can be used to treat respiratory diseases, cancer, inflammatory diseases, and/or autoinflammatory/autoimmune diseases. Formula (A): Rand Rare herein defined throughout the disclosure.

Substituted indazoles as IRAK4 inhibitors

Disclosed herein are compounds of Formula (I), and pharmaceutically acceptable salts thereof, wherein R-Rhave any of the meanings defined herein. Also disclosed are pharmaceutical compositions comprising compounds of Formula (I) and methods of using the same.

JAK1 selective inhibitors

The present application relates to chemical compounds of Formula (A): and pharmaceutically acceptable salts thereof, wherein X, R, and Rare as defined herein. The chemical compounds of Formula (A) inhibit IRAKand consequently have potential utility in medicine.

The present invention relates to compounds of formula (I), and pharmaceutically acceptable salts, prodrugs, solvates and crystalline forms thereof, in which Rand Rindependently represent: a Calkyl group; an optionally substituted (amino)Calkyl-group; an optionally substituted non-aromatic Ccarbocyclic group; a (Ccycloalkyl)Calkyl-group; a group &#x2014;(CH)(phenyl)in which r is 0, 1, 2, 3 or 4, s is 1 when r is 0 otherwise s is 1 or 2 and the phenyl groups are optionally independently substituted by Z; naphthyl; anthracenyl; an optionally substituted saturated 5 to 8 membered heterocyclic group containing one nitrogen and optionally one of the following: oxygen, sulphur or an additional nitrogen; 1-adamantylmethyl; a group &#x2014;(CH)Het in which t is 0, 1, 2, 3 or 4, and the alkylene chain is optionally substituted and Het represents an optionally substituted aromatic heterocycle; or Rrepresents H and Ris as defined above; or Rand Rtogether with the nitrogen atom to which they are attached represent a saturated optionally substituted 5 to 8 membered heterocyclic group as defined above; X is CO or SO; Y is absent or represents NH optionally substitututed by a Calkyl group; Rand Rindependently represent phenyl, thienyl or pyridyl substituted by Z; Z represents a Calkyl group, a Calkoxy group, hydroxy, halo, trifluoromethyl, trifluoromethylthio, trifluoromethoxy, trifluoromethylsulphonyl, nitro, amino, mono or di Calkylamino, mono or di Calkylamido, Calkylsulphonyl, Calkoxycarbonyl, carboxy, cyano, carbamoyl, mono or di Calkyl carbamoyl, sulphamoyl and acetyl; and Ris H, a Calkyl group, a Calkoxymethyl group, trifluoromethyl, a hydroxyCalkyl group, Calkoxycarbonyl, carboxy, cyano, carbamoyl, mono or di Calkylcarbamoyl, acetyl, or hydrazinocarbonyl of formula &#x2014;CONHNRR; with the provisos; and processes for preparing such compounds, their use in the treatment of obesity, psychiatric and neurological disorders, to methods for their therapeutic use and to pharmaceutical compositions containing them.

[object Object]

Growing community of inventors

Mölndal, Sweden

Anna Ingrid Kristina Berggren